Europe
Under the terms of the acquisition, Bayer is buying the rest of the company for $240 million up front with an additional $360 million in various development milestones. This will correspond with the company’s value of about $1 billion.
The company withdrew its initial BLA in December after the FDA requested more information regarding manufacturing procedures and quality controls.
Former Touch Bionics CEO joins Adapttech as company secures FDA decision for medical device that improves prosthesis fit
Epigenomics AG announced the operational achievements plus financial results for the second quarter and the first half of 2019.
Quanta Dialysis Technologies Ltd, a British medical technology company developing a personal haemodialysis system for patient use in the clinic and the home, announces that it has begun human factors testing of SC+ in the United States with Design Science, a leading specialist in medical device usability.
Conference call and webcast, August 07, 2019 at 3:00 pm CET, 9:00 am EST
NOXXON Pharma N.V. announced that following discussions with investors it has received letters of intent and binding commitments for long-term investment of €1 million through a private placement plus additional commitment for a future private placement.
Big Data falls short - the consulting company MAIN5 presents study “Pharma Insights 2019"
MorphoSys AG announced its intention to submit a Marketing Authorization Application to the European Medicines Agency based on its phase 2 L-MIND study of tafasitamab and lenalidomide in relapsed or refractory diffuse large B cell lymphoma.
Biopharma companies from across the globe share business and development updates.
PRESS RELEASES